AbCellera reported a strong fourth quarter in 2025, driven by a significant patent litigation settlement that accounted for 60% of the year's total revenue. The company successfully transitioned into a clinical-stage biotech with two internal programs in trials and maintained a robust liquidity position of approximately $700 million.

AbCellera reported a total revenue of $4.2 million for Q1 2025, a decrease from $10.0 million in Q1 2024. The company experienced a net loss of $45.6 million, compared to a net loss of $40.6 million in the prior year. Despite the loss, AbCellera maintained strong liquidity with over $800 million in available funds and is advancing new antibody programs into clinical trials.

AbCellera reported Q4 2024 revenue of $5.1 million and a net loss of $34.2 million. The company continues to advance its pipeline and invest in its capabilities.

AbCellera reported total revenue of $6.5 million, a net loss of $51.1 million, and continued investment in research and development. The company also expanded its collaboration with Eli Lilly and Company and maintained a strong liquidity position with over $875 million available.

AbCellera reported a revenue of $7.3 million, with research fees contributing $5.5 million and milestone payments contributing $1.5 million. The company's net loss was $36.9 million, or $(0.13) per share.

AbCellera reported a decrease in revenue to $10.0 million compared to $12.2 million in Q1 2023. Net loss was $40.6 million, or $(0.14) per share, compared to a net loss of $40.1 million, or $(0.14) per share in Q1 2023. The company had $725.3 million in total cash, cash equivalents, and marketable securities.

AbCellera reported Q4 2023 revenue of $9.2 million, representing 24% of the total revenue for 2023. The company experienced a net loss of $47.2 million, or $(0.16) per share. They advanced two internal programs into IND-enabling studies and saw three partner-initiated programs start with downstreams.

AbCellera reported a significant decrease in revenue to $6.6 million compared to $101.4 million in Q3 2022. The company had a net loss of $28.6 million, or $(0.10) per share, compared to net earnings of $26.6 million in Q3 2022. They reached a cumulative total of 110 partnered program starts and advanced one additional molecule into the clinic, bringing the cumulative total to ten molecules.

AbCellera reported Q2 2023 results with a total revenue of $10.1 million, a net loss of $30.5 million, and secured over $220 million in strategic financing, bringing total available liquidity to over $1 billion.

AbCellera reported Q1 2023 financial results, with a total revenue of $12.2 million compared to $316.6 million in Q1 2022. The company generated a net loss of $40.1 million, or $(0.14) per share, compared to net earnings of $168.6 million, or $0.59 per share in Q1 2022. They reached a cumulative total of 177 programs under contract and maintained 101 partnered program starts. One additional molecule was advanced into the clinic, bringing the cumulative total to nine molecules.

AbCellera's Q4 2022 saw revenue of $21.5 million, with $9.5 million from royalties and $11.4 million from research fees. The company experienced a net loss of $29.9 million, or ($0.10) per share.

AbCellera reported a significant increase in revenue for Q3 2022, driven primarily by royalties associated with bebtelovimab. The company also saw growth in research fees and advancements in its discovery programs, resulting in a net income compared to a net loss in the same quarter of the previous year. AbCellera maintains a strong cash position to support its strategic initiatives.

AbCellera reported total revenue of $46 million, driven by royalties associated with bebtelovimab and research fees from the partnership business. The company incurred a net loss of $7 million, or ($0.02) per share. They strengthened their balance sheet and continue to invest in technology development.

AbCellera announced financial results for the first quarter of 2022, with total revenue of $317 million and net earnings of $169 million. The company saw growth in program starts and molecules advancing into the clinic.

AbCellera's Q4 2021 revenue reached $139.3 million, with royalties on bamlanivimab sales contributing $134.5 million and research fees accounting for $4.7 million. Net earnings for the quarter were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.

AbCellera reported a decrease in total revenue to $5.5 million compared to $9.4 million in Q3 2020, which is attributable to the reduction of milestone payments associated with COVID-19 treatments. The company added 17 programs under contract and two new partners, resulting in a cumulative total of 155 programs under contract with 35 different partners. One new molecule advanced into the clinic, bringing the cumulative total to five. The net loss was $21.4 million, or ($0.08) per share.

AbCellera reported Q2 2021 financial results with a total revenue of $27.6 million, up from $11 million in Q2 2020. The company incurred a net loss of $2.3 million, compared to net earnings of $6.7 million in Q2 2020.

AbCellera reported a significant increase in revenue for Q1 2021, driven by milestone payments and royalties. The company also generated substantial net earnings, a stark contrast to the net loss reported in the same quarter of the previous year. Partnership business expanded, and a second therapeutic antibody for COVID-19 advanced into clinical trials.